SequelSEC

Zai Lab Ltd ZLAB

Pharmaceutical Preparations · CIK 0001704292 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$106.31M
Fiscal year ended 2026-06-30
Operating income
-$76.49M
Fiscal year ended 2026-06-30
Free cash flow
-$64.72M
Fiscal year ended 2026-06-30

Zai Lab Ltd (ZLAB) reported revenue of $106.31M and net income of -$50.82M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Zai Lab Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Zai Lab Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$106.31M$99.61M$127.60M$116.10M$109.98M$106.49M$109.07M$102.26M$100.50M$87.15M
Cost of revenue$48.16M$38.32M$62.30M$46.76M$43.00M$38.45M$41.78M$36.57M$35.15M$33.62M
Gross profit$58.15M$61.30M$65.30M$69.33M$66.97M$68.04M$67.29M$65.70M$65.36M$53.53M
Operating income-$76.49M-$69.38M-$69.41M-$48.82M-$54.90M-$56.31M-$67.89M-$67.85M-$76.06M-$70.31M
Net income-$50.82M-$51.02M-$50.41M-$35.96M-$40.73M-$48.44M-$81.68M-$41.67M-$80.28M-$53.47M
Research & development$61.77M$65.59M$61.63M$47.93M$50.61M$60.73M$52.25M$65.98M$61.62M$54.64M
Weighted-average diluted sharesshares 1.12Bshares 1.11BUnavailableshares 1.10Bshares 1.09Bshares 1.08BUnavailableshares 981.69Mshares 975.94Mshares 973.15M
Pretax income-$51.85M-$49.58M-$53.34M-$35.96M-$40.73M-$48.44M-$81.68M-$41.67M-$80.28M-$53.47M
Income tax expense-$1.02M$1.44M-$2.93M$0$0$0$0$0$0$0
Diluted EPS$-0.05$-0.05Unavailable$-0.03$-0.04$-0.04Unavailable$-0.04$-0.08$-0.05
Selling, general & administrative$72.87M$65.07M$73.04M$70.11M$71.04M$63.42M$82.62M$67.22M$79.71M$69.19M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Zai Lab Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$607.52M$651.32M$679.57M$717.16M$732.16M$757.26M$449.67M$616.09M$630.05M$650.78M
Total assets$1.07B$1.10B$1.17B$1.16B$1.16B$1.17B$1.19B$985.35M$987.37M$988.44M
Current assets$914.04M$944.73M$1.02B$1.03B$1.03B$1.04B$1.05B$860.55M$869.92M$888.64M
Total liabilities$467.76M$433.76M$456.88M$399.00M$372.37M$362.58M$344.86M$317.68M$283.19M$226.27M
Current liabilities$428.58M$392.98M$416.17M$359.77M$331.50M$319.81M$299.38M$286.32M$251.72M$192.11M
Total equity incl. NCI$607.04M$661.98M$715.50M$759.94M$791.74M$810.75M$840.90M$667.67M$704.18M$762.17M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$90.89M$85.96M$74.74M$67.14M$61.70M$53.05M$39.88M$39.55M$41.85M$37.85M
Accounts receivable$69.60M$54.07M$106.12M$85.38M$88.50M$76.56M$85.18M$49.97M$69.64M$60.42M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$136.69M$126.17M$141.61M$99.71M$107.36M$103.02M$100.91M$120.65M$127.34M$88.12M

Cash flow

Zai Lab Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$63.41M-$11.91M-$26.02M-$32.04M-$31.02M-$61.70M-$55.77M-$26.82M-$42.17M-$90.11M
Capital expenditures$1.31M$1.20M$677.00K$3.00M$2.88M$1.53M$2.60M$1.34M$741.00K$974.00K
Investing cash flow-$1.42M-$22.29M-$11.30M-$4.05M-$2.92M$326.13M-$347.75M-$29.88M-$846.00K$3.29M
Financing cash flow$18.70M$5.57M-$430.00K$20.79M$8.85M$43.14M$237.81M$42.21M$22.32M$47.55M
Net change in cash-$43.79M-$28.26M-$37.58M-$15.11M-$24.99M$307.60M-$166.42M-$13.96M-$20.73M-$39.37M
Stock-based compensation$11.94M$13.52M$15.90M$16.92M$16.97M$15.80M$17.24M$16.80M$18.64M$17.98M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.17M$3.94M$3.92M$3.90M$3.74M$3.46M$3.03M$2.87M$2.94M$3.01M

Derived

Zai Lab Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$64.72M-$13.11M-$26.70M-$35.05M-$33.91M-$63.23M-$58.37M-$28.16M-$42.91M-$91.08M
Gross margin54.7%61.5%51.2%59.7%60.9%63.9%61.7%64.2%65.0%61.4%
Operating margin-71.9%-69.7%-54.4%-42.1%-49.9%-52.9%-62.2%-66.4%-75.7%-80.7%
FCF margin-60.9%-13.2%-20.9%-30.2%-30.8%-59.4%-53.5%-27.5%-42.7%-104.5%
SBC / revenue11.2%13.6%12.5%14.6%15.4%14.8%15.8%16.4%18.5%20.6%
Current ratio2.13x2.40x2.45x2.87x3.12x3.26x3.51x3.01x3.46x4.63x
Revenue YoY growth-3.3%-6.5%17.0%13.5%9.4%22.2%65.7%47.7%45.9%38.8%
Net margin-47.8%Unavailable-39.5%-31.0%-37.0%Unavailable-74.9%-40.7%UnavailableUnavailable
R&D / revenue58.1%65.8%48.3%41.3%46.0%57.0%47.9%64.5%61.3%62.7%
CapEx / revenue1.2%1.2%0.5%2.6%2.6%1.4%2.4%1.3%0.7%1.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZLAB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.